Moleculin Biotech Inc (MBRX) concluded trading on Thursday at a closing price of $0.84, with 9.47 million shares of worth about $7.96 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -55.32% during that period and on July 17, 2025 the price saw a gain of about 30.56%. Currently the company’s common shares owned by public are about 30.21M shares, out of which, 27.57M shares are available for trading.
Stock saw a price change of 56.48% in past 5 days and over the past one month there was a price change of 21.95%. Year-to-date (YTD), MBRX shares are showing a performance of -80.23% which decreased to -50.85% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.25 but also hit the highest price of $4.71 during that period. The average intraday trading volume for Moleculin Biotech Inc shares is 4.55 million. The stock is currently trading 86.29% above its 20-day simple moving average (SMA20), while that difference is up 19.69% for SMA50 and it goes to -44.00% lower than SMA200.
Moleculin Biotech Inc (NASDAQ: MBRX) currently have 30.21M outstanding shares and institutions hold larger chunk of about 4.89% of that.
The stock has a current market capitalization of $25.24M and its 3Y-monthly beta is at 1.29. It has posted earnings per share of -$5.80 in the same period. It has Quick Ratio of 1.35 while making debt-to-equity ratio of 11.25. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MBRX, volatility over the week remained 24.28% while standing at 20.96% over the month.
Stock’s fiscal year EPS is expected to rise by 75.21% while it is estimated to increase by 13.19% in next year. EPS is likely to grow at an annualized rate of 42.60% for next 5-years, compared to annual growth of 26.36% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on June 09, 2025 offering a Buy rating for the stock and assigned a target price of $4 to it.
